NOTIFICATION

Addendum

The following communication, dated 11 August 2022, is being circulated at the request of the delegation of the Philippines.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Title:** Guidelines on Regulatory Reliance on the Conduct of Clinical Trials in the Philippines

|  |
| --- |
| **Reason for Addendum:** |
| [ ] | Comment period changed - date:  |
| [ ] | Notified measure adopted - date:  |
| [ ] | Notified measure published - date:  |
| [ ] | Notified measure enters into force - date:  |
| [ ] | Text of final measure available from[[1]](#footnote-1):  |
| [ ] | Notified measure withdrawn or revoked - date: Relevant symbol if measure re-notified:  |
| [X] | Content or scope of notified measure changed and text available from1: <https://www.fda.gov.ph/draft-for-comments-guidelines-on-regulatory-reliance-on-the-conduct-of-clinical-trials-in-the-philippines-2/><https://members.wto.org/crnattachments/2022/TBT/PHL/modification/22_5469_00_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/modification/22_5469_01_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/modification/22_5469_02_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/modification/22_5469_03_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/modification/22_5469_04_e.pdf>New deadline for comments (if applicable): 23 August 2022 |
| [ ] | Interpretive guidance issued and text available from1:  |
| [ ] | Other:  |

**Description:** There are major changes on the issuance, specifically on the objectives, scope and coverage and application process.

**\_\_\_\_\_\_\_\_\_\_**

1. This information can be provided by including a website address, a pdf attachment, or other information on where the text of the final/modified measure and/or interpretive guidance can be obtained. [↑](#footnote-ref-1)